DENTSPLY SIRONA Past Earnings Performance
Past criteria checks 0/6
DENTSPLY SIRONA's earnings have been declining at an average annual rate of -40.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 1.2% per year.
Key information
-40.9%
Earnings growth rate
-41.1%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 1.2% |
Return on equity | -16.5% |
Net Margin | -10.6% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Now An Opportune Moment To Examine DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Dec 21DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 40% Below Their Intrinsic Value Estimate
Dec 03Dentsply Sirona: No Change To Operating Mechanics Despite Extensive Review
Nov 27DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Nov 11DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Revenue & Expenses Breakdown
How DENTSPLY SIRONA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 3,900 | -413 | 1,612 | 166 |
30 Jun 24 | 3,896 | -185 | 1,596 | 172 |
31 Mar 24 | 3,940 | -95 | 1,611 | 180 |
31 Dec 23 | 3,965 | -132 | 1,617 | 184 |
30 Sep 23 | 3,936 | -214 | 1,612 | 184 |
30 Jun 23 | 3,936 | -1,025 | 1,641 | 179 |
31 Mar 23 | 3,931 | -1,038 | 1,638 | 175 |
31 Dec 22 | 3,922 | -950 | 1,596 | 174 |
30 Sep 22 | 4,042 | -816 | 1,564 | 180 |
30 Jun 22 | 4,135 | 345 | 1,552 | 178 |
31 Mar 22 | 4,174 | 368 | 1,536 | 176 |
31 Dec 21 | 4,231 | 411 | 1,547 | 171 |
30 Sep 21 | 4,207 | 401 | 1,535 | 166 |
30 Jun 21 | 4,062 | 370 | 1,458 | 154 |
31 Mar 21 | 3,491 | 179 | 1,323 | 129 |
31 Dec 20 | 3,339 | -73 | 1,309 | 123 |
30 Sep 20 | 3,371 | -80 | 1,275 | 210 |
30 Jun 20 | 3,438 | -48 | 1,340 | 183 |
31 Mar 20 | 3,957 | 84 | 1,510 | 165 |
31 Dec 19 | 4,022 | 256 | 1,578 | 143 |
30 Sep 19 | 3,977 | 162 | 1,520 | 161 |
30 Jun 19 | 3,944 | 105 | 1,560 | 161 |
31 Mar 19 | 3,976 | -1,053 | 1,562 | 161 |
31 Dec 18 | 3,986 | -1,011 | 1,551 | 161 |
30 Sep 18 | 4,018 | -1,663 | 1,560 | 152 |
30 Jun 18 | 4,098 | -1,601 | 1,578 | 152 |
31 Mar 18 | 4,049 | -1,529 | 1,563 | 152 |
31 Dec 17 | 3,993 | -1,550 | 1,532 | 152 |
30 Sep 17 | 3,899 | -793 | 1,501 | 129 |
30 Jun 17 | 3,844 | -791 | 1,443 | 129 |
31 Mar 17 | 3,873 | 365 | 1,427 | 129 |
31 Dec 16 | 3,745 | 430 | 1,374 | 129 |
30 Sep 16 | 3,420 | 382 | 1,307 | 75 |
30 Jun 16 | 3,115 | 374 | 1,192 | 75 |
31 Mar 16 | 2,791 | 312 | 1,065 | 75 |
31 Dec 15 | 2,674 | 251 | 993 | 75 |
30 Sep 15 | 2,722 | 277 | 1,011 | 81 |
30 Jun 15 | 2,782 | 268 | 1,017 | 81 |
31 Mar 15 | 2,849 | 314 | 1,038 | 81 |
31 Dec 14 | 2,923 | 323 | 1,062 | 81 |
30 Sep 14 | 2,957 | 313 | 1,061 | 85 |
30 Jun 14 | 2,953 | 317 | 1,060 | 85 |
31 Mar 14 | 2,949 | 314 | 1,054 | 85 |
31 Dec 13 | 2,951 | 313 | 1,060 | 85 |
Quality Earnings: XRAY is currently unprofitable.
Growing Profit Margin: XRAY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XRAY is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.
Accelerating Growth: Unable to compare XRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: XRAY has a negative Return on Equity (-16.47%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 01:43 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DENTSPLY SIRONA Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Baird |
Jeffrey Johnson | Baird |
Ishan Majumdar | Baptista Research |